انتقل إلى المحتوى
Peerford
تسجيل الدخول
Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months · Peerford